Centanafadine (
INN
Inns are generally establishments or buildings where travelers can seek lodging, and usually, food and drink. Inns are typically located in the country or along a highway; before the advent of motorized transportation they also provided accommo ...
) (former developmental code name EB-1020) is a
serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that began its
development with
Euthymics Bioscience after they acquired
DOV Pharmaceutical. It was developed as a treatment for
attention-deficit hyperactivity disorder
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterised by excessive amounts of inattention, hyperactivity, and impulsivity that are pervasive, impairing in multiple contexts, and otherwise age-inappro ...
(ADHD) and inhibits the
reuptake
Reuptake is the reabsorption of a neurotransmitter by a neurotransmitter transporter located along the plasma membrane of an axon terminal (i.e., the pre-synaptic neuron at a synapse) or glial cell after it has performed its function of trans ...
of
norepinephrine
Norepinephrine (NE), also called noradrenaline (NA) or noradrenalin, is an organic chemical in the catecholamine family that functions in the brain and body as both a hormone and neurotransmitter. The name "noradrenaline" (from Latin '' ad ...
,
dopamine
Dopamine (DA, a contraction of 3,4-dihydroxyphenethylamine) is a neuromodulatory molecule that plays several important roles in cells. It is an organic chemical of the catecholamine and phenethylamine families. Dopamine constitutes about 8 ...
, and
serotonin with a ratio of 1:6:14, respectively.
In 2011,
Euthymics Bioscience spun off its development of centanafadine to a new company called Neurovance.
In March 2017, Otsuka Pharmaceutical acquired Neurovance and the rights to centanafadine. As of January 2018, Otsuka's pipeline indicates it is in Phase III clinical trials.
See also
*
Amitifadine
Amitifadine (developmental code names DOV-21,947, EB-1010) is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) or so-called triple reuptake inhibitor (TRI) which is or was being developed by Euthymics Bioscience It was under de ...
*
Bicifadine
*
Dasotraline
Dasotraline (INN; former developmental code name SEP-225,289) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that was under development by Sunovion for the treatment of attention-deficit hyperactivity disorder (ADHD) and bing ...
*
DOV-216,303
*
Tesofensine
References
External links
Centanafadine - AdisInsight
2-Naphthyl compounds
Serotonin–norepinephrine–dopamine reuptake inhibitors
Stimulants
Nitrogen heterocycles
Cyclopropanes
{{nervous-system-drug-stub